Cargando…
A Pharmacologic Approach to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Smoking Related Lung Disease
BACKGROUND: Mucus stasis in chronic obstructive pulmonary disease (COPD) is a significant contributor to morbidity and mortality. Potentiators of cystic fibrosis transmembrane conductance regulator (CFTR) activity pharmacologically enhance CFTR function; ivacaftor is one such agent approved to treat...
Autores principales: | Sloane, Peter A., Shastry, Suresh, Wilhelm, Andrew, Courville, Clifford, Tang, Li Ping, Backer, Kyle, Levin, Elina, Raju, S. Vamsee, Li, Yao, Mazur, Marina, Byan-Parker, Suzanne, Grizzle, William, Sorscher, Eric J., Dransfield, Mark T., Rowe, Steven M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387224/ https://www.ncbi.nlm.nih.gov/pubmed/22768130 http://dx.doi.org/10.1371/journal.pone.0039809 |
Ejemplares similares
-
Acquired cystic fibrosis transmembrane conductance regulator dysfunction
por: Banks, Catherine, et al.
Publicado: (2018) -
Acquired defects in CFTR-dependent β-adrenergic sweat secretion in chronic obstructive pulmonary disease
por: Courville, Clifford A, et al.
Publicado: (2014) -
Method for Quantitative Study of Airway Functional Microanatomy Using Micro-Optical Coherence Tomography
por: Liu, Linbo, et al.
Publicado: (2013) -
Glycosylation and the cystic fibrosis transmembrane conductance regulator
por: Scanlin, Thomas F, et al.
Publicado: (2001) -
Where Is the Cystic Fibrosis Transmembrane Conductance Regulator?
por: Barbry, Pascal, et al.
Publicado: (2021)